Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Long noncoding RNAs (lncRNAs) have been identified to have increasingly important roles in tumorigenesis, and they may serve as novel biomarkers for cancer therapy. Recent studies have demonstrated that lncRNA
NBR2
(neighbor of BRCA1 gene 2), a novel identified lncRNA, is decreased in several cancers; however, the role of
NBR2
in the development of
osteosarcoma
has not been elucidated. In our study, we found that
NBR2
expression was downregulated in
osteosarcoma
tissues, and
osteosarcoma
cases with lower
NBR2
expression exhibited a shorter overall survival time compared with those with higher
NBR2
expression.
NBR2
overexpression inhibited
osteosarcoma
cell proliferation, invasion, and migration but did not increase apoptosis. Furthermore, RNA-binding protein immunoprecipitation assays confirmed that
NBR2
directly binds to Notch1 protein. Furthermore, overexpression of Notch1 in
NBR2
-overexpressing
osteosarcoma
cells reversed the effects of
NBR2
on cell proliferation, invasion, migration, and epithelial-mesenchymal transition. The in vivo results showed that
NBR2
overexpression inhibited tumor growth in nude mice that were inoculated with
osteosarcoma
cells.
NBR2
overexpression also suppressed the messenger RNA (mRNA) expression of Notch1, N-cadherin, and vimentin and increased the mRNA expression of E-cadherin in the tumor tissues. These data indicated that
NBR2
served as a tumor suppressor gene in
osteosarcoma
and inhibited
osteosarcoma
cell proliferation, invasion, and migration. The current study provides a novel insight and treatment strategy for
osteosarcoma
.
...
PMID:LncRNA NBR2 inhibits epithelial-mesenchymal transition by regulating Notch1 signaling in osteosarcoma cells. 3018 65